The degradation (by distinct pathways) of human D-amino acid oxidase and its interacting partner pLG72 - two key proteins in D-serine catabolism in the brain

FEBS Journal

Volumn 281, Issue 3, 2014, Pages 708-723

  Cappelletti, Pamela ^a   Campomenosi, Paola ^a   Pollegioni, Loredano ^a   Sacchi, Silvia ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

D serine; Degradation pathway; Neuromodulator; Regulation; Schizophrenia

Indexed keywords

BINDING PROTEIN; CYAN FLUORESCENT PROTEIN; DEXTRO AMINO ACID OXIDASE; DEXTRO SERINE; HUMAN DEXTRO AMINO ACID OXIDASE; PROTEASOME; PROTEIN PLG72; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN;

ARTICLE; BRAIN; CATABOLISM; CONTROLLED STUDY; CYTOSOL; ENDOSOME; HUMAN; HUMAN CELL; LYSOSOME; MITOCHONDRION; PEROXISOME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; UBIQUITINATION;

MAMMALIA;

D-SERINE; DEGRADATION PATHWAY; NEUROMODULATOR; REGULATION; SCHIZOPHRENIA;

BACTERIAL PROTEINS; BRAIN; CARRIER PROTEINS; CELL LINE, TUMOR; CYTOSOL; D-AMINO-ACID OXIDASE; ENDOSOMES; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; LYSOSOMES; MITOCHONDRIA; NERVE TISSUE PROTEINS; NEURONS; PEROXISOMES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; PROTEOLYSIS; RECOMBINANT FUSION PROTEINS; UBIQUITINATION;

EID: 84897042700     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12616     Document Type: Article

References (58)

1. Fields RD & Stevens-Graham B (2002) New insights into neuron-glia communication. Science 298, 556-562.
2. Volterra A & Meldolesi J (2005) Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci 6, 626-640.
3. Mustafa AK, Kim PM & Snyder SH (2004) D-Serine as a putative glial neurotransmitter. Neuron Glia Biol 1, 275-281.
4. Martineau M, Baux G & Mothet JP (2006) D-Serine signalling in the brain: friend and foe. Trends Neurosci 29, 481-491.
5. Papouin T, Ladépêche L, Ruel J, Sacchi S, Labasque M, Hanini M, Groc L, Pollegioni L, Mothet JP & Oliet SH (2012) Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 150, 633-646.
6. Gustafson EC, Stevens ER, Wolosker H & Miller RF (2007) Endogenous D-serine contributes to NMDA receptor-mediated light-evoked responses in the vertebrate retina. J Neurophysiol 98, 122-130.
7. Mothet JP, Parent AT, Wolosker H, Brady RO Jr, Linden DJ, Ferris CD, Rogawski MA & Snyder SH (2000) D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 97, 4926-4931.
8. Kartvelishvily E, Shleper M, Balan L, Dumin E & Wolosker H (2006) Neuron-derived D-serine release provides a novel means to activate N-methyl-Daspartate receptors. J Biol Chem 281, 14151-14162.
9. Panatier A, Theodosis DT, Mothet JP, Touquet B, Pollegioni L, Poulain DA & Oliet SH (2006) Glia derived D-serine controls NMDA receptor activity and synaptic memory. Cell 125, 775-784.
10. Yang Y, Ge W, Chen Y, Zhang Z, Shen W, Wu C, Poo M & Duan S (2003) Contribution of astrocytes to hippocampal long-term potentiation through release of D-serine. Proc Natl Acad Sci USA 100, 15194-15199.
11. Foltyn VN, Bendikov I, De Miranda J, Panizzutti R, Dumin E, Shleper M, Li P, Toney MD, Kartvelishvily E & Wolosker H (2005) Serine racemase modulates intracellular D-serine levels through an a, b-elimination activity. J Biol Chem 280, 1754-6173.
12. Wolosker H, Blackshaw S & Snyder SH (1999) Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc Natl Acad Sci USA 96, 13409-13414.
13. Pollegioni L, Piubelli L, Sacchi S, Pilone MS & Molla G (2007) Physiological functions of D-amino acid oxidases: from yeast to humans. Cell Mol Life Sci 64, 1373-1394.
14. Pollegioni L & Sacchi S (2010) Metabolism of the neuromodulator D-serine. Cell Mol Life Sci 67, 2387-2404.
15. Billard JM (2012) D-Amino acids in brain neurotransmission and synaptic plasticity. Amino Acids 43, 1851-1860.
16. Kantrowitz JT & Javitt DC (2010) N-methyl-Daspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull 83, 108-121.
17. Labrie V, Wong AH & Roder JC (2012) Contributions of the D-serine pathway to schizophrenia. Neuropharmacology 62, 1484-1503.
18. Bendikov I, Nadri C, Amar S, Panizzutti R, De Miranda J, Wolosker H & Agam G (2007) A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res 90, 41-51.
19. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H et al. (2003) Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60, 572-576.
20. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindström LH & Iyo M (2005) Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 29, 767-769.
21. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S & Ermilov M (2005) D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 57, 577-585.
22. Tsai G, Yang P, Chung LC, Lange N & Coyle JT (1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44, 1081-1089.
23. Kapoor R, Lim KS, Cheng A, Garrick T & Kapoor V (2006) Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, D-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1). Brain Res 1106, 205-210.
24. Madeira C, Freitas ME, Vargas-Lopes C, Wolosker H & Panizzutti R (2008) Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res 101, 76-83.
25. Burnet PW, Hutchinson L, von Hesling M, Gilbert EJ, Brandon NJ, Rutter AR, Hutson PH & Harrison PJ (2008) Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia. Schizophr Res 102, 283-294.
26. Verrall L, Walker M, Rawlings N, Benzel I, Kew JN, Harrison PJ & Burnet PW (2007) D-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. Eur J Neurosci 26, 1657-1669.
27. Ono K, Shishido Y, Park HK, Kawazoe T, Iwana S, Chung SP, Abou El-Magd RM, Yorita K, Okano M, Watanabe T et al. (2009) Potential pathophysiological role of D-amino acid oxidase in schizophrenia: immunohistochemical and in situ hybridization study of the expression in human and rat brain. J Neural Transm 116, 1335-1347.
28. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, Bougueleret L, Barry C, Tanaka H, La Rosa P et al. (2002) Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci USA 99, 13675-13680.
29. Sacchi S, Bernasconi M, Martineau M, Mothet JP, Ruzzene M, Pilone MS, Pollegioni L & Molla G (2008) pLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase: effect on schizophrenia susceptibility. J Biol Chem 283, 22244-22256.
30. Williams SM, Diaz CM, Macnab LT, Sullivan RK & Pow DV (2006) Immunocytochemical analysis of Dserine distribution in the mammalian brain reveals novel anatomical compartmentalizations in glia and neurons. Glia 53, 401-411.
31. Horiike K, Tojo H, Arai R, Nozaki M & Maeda T (1994) D-amino-acid oxidase is confined to the lower brain stem and cerebellum in rat brain: regional differentiation of astrocytes. Brain Res 652, 297-303.
32. Sacchi S, Cappelletti P, Giovannardi S & Pollegioni L (2011) Evidence for the interaction of D-amino acid oxidase with pLG72 in a glial cell line. Mol Cell Neurosci 48, 20-28.
33. Popiolek M, Ross JF, Charych E, Chanda P, Gundelfinger ED, Moss SJ, Brandon NJ & Pausch MH (2011) D-amino acid oxidase activity is inhibited by an interaction with bassoon protein at the presynaptic active zone. J Biol Chem 286, 28867-28875.
34. Kvajo M, Dhilla A, Swor DE, Karayiorgou M & Gogos JA (2008) Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function. Mol Psychiatry 13, 685-696.
35. Benzel I, Kew JN, Viknaraja R, Kelly F, de Belleroche J, Hirsch S, Sanderson TH & Maycox PR (2008) Investigation of G72 (DAOA) expression in the human brain. BMC Psychiatry 8, 94.
36. Otte DM, Bilkei-Gorzó A, Filiou MD, Turck CW, Yilmaz O, Holst MI, Schilling K, Abou-Jamra R, Schumacher J, Benzel I et al. (2009) Behavioral changes in G72/G30 transgenic mice. Eur Neuropsychopharmacol 19, 339-348.
37. Caldinelli L, Molla G, Bracci L, Lelli B, Pileri S, Cappelletti P, Sacchi S & Pollegioni L (2010) Effect of ligand binding on human D-amino acid oxidase: implications for the development of new drugs for schizophrenia treatment. Protein Sci 19, 1500-1512.
38. Fossat P, Turpin FR, Sacchi S, Dulong J, Shi T, Rivet JM, Sweedler JV, Pollegioni L, Millan MJ, Oliet SH et al. (2012) Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex. Cereb Cortex 22, 595-606.
39. Dumin E, Bendikov I, Foltyn VN, Misumi Y, Ikehara Y, Kartvelishvily E & Wolosker H (2006) Modulation of D-serine levels via ubiquitin-dependent proteasomal degradation of serine racemase. J Biol Chem 281, 20291-20302.
40. Groll M & Huber R (2004) Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim Biophys Acta 1695, 33-44.
41. Koh YH, von Arnim CA, Hyman BT, Tanzi RE & Tesco G (2005) BACE is degraded via the lysosomal pathway. J Biol Chem 280, 32499-32504.
42. Ding X, Ma N, Nagahama M, Yamada K & Semba R (2011) Localization of D-serine and serine racemase in neurons and neuroglias in mouse brain. Neurol Sci 32, 263-267.
43. Rosenberg D, Kartvelishvily E, Shleper M, Klinker CM, Bowser MT & Wolosker H (2010) Neuronal release of D-serine: a physiological pathway controlling extracellular D-serine concentration. FASEB J 24, 2951-2961.
44. Wolosker H (2011) Serine racemase and the serine shuttle between neurons and astrocytes. Biochim Biophys Acta 181, 1558-1566.
45. Molla G, Sacchi S, Bernasconi M, Pilone MS, Fukui K & Pollegioni L (2006) Characterization of human D-amino acid oxidase. FEBS Lett 580, 2358-2364.
46. Hicke L (2001) A new ticket for entry into budding vesicles-ubiquitin. Cell 106, 527-530.
47. Korolchuk VI, Mansilla A, Menzies FM & Rubinsztein DC (2009) Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 33, 517-527.
48. Jiang N, Shen Y, Fei X, Sheng K, Sun P, Qiu Y, Larner J, Cao L, Kong X & Mi J (2013) Valosincontaining protein regulates the proteasome-mediated degradation of DNA-PKcs in glioma cells. Cell Death Dis 4, e647.
49. Wong E & Cuervo AM (2010) Integration of clearance mechanisms: the proteasome and autophagy. Cold Spring Harbor Perspect Biol 2, a006734.
50. Karbowski M & Youle RJ (2011) Regulating mitochondrial outer membrane proteins by ubiquitination and proteasomal degradation. Curr Opin Cell Biol 23, 476-482.
51. Livnat-Levanon N & Glickman MH (2011) Ubiquitinproteasome system and mitochondria-reciprocity. Biochim Biophys Acta 1809, 80-87.
52. Kalejta RF & Shenk T (2003) Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. Proc Natl Acad Sci USA 100, 3263-3268.
53. Kravtsova-Ivantsiv Y & Ciechanover A (2012) Noncanonical ubiquitin-based signals for proteasomal degradation. J Cell Sci 125, 539-548.
54. Smith SM, Uslaner JM & Hutson PH (2010) The therapeutic potential of D-amino acid oxidase (DAAO) inhibitors. Open Med Chem J 4, 3-9.
55. Sacchi S, Rosini E, Pollegioni L & Molla G (2013) D-amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy. Curr Pharm Des 19, 2499-2511.
56. Ley R, Balmanno K, Hadfield K, Weston C & Cook SJ (2003) Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278, 18811-18816.
57. Leithe E & Rivedal E (2004) Epidermal growth factor regulates ubiquitination, internalization and proteasome-dependent degradation of connexin43. J Cell Sci 117, 1211-1220.
58. Molla G, Bernasconi M, Sacchi S, Pilone MS & Pollegioni L (2006) Expression in Escherichia coli and in vitro refolding of the human protein pLG72. Protein Expr Purif 46, 150-155.